WS #13405
Holding: newest synthesis is 98d 14h old
Novo Nordisk raised its 2026 outlook on strong GLP-1 sales, but shares fell on a flat outlook and a DKK 6.3B impairment, highlighting competitive pressure from Eli Lilly.
Novo Nordisk guidance raise
Novo Nordisk raised its 2026 outlook on strong GLP-1 sales, but shares fell on a flat outlook and a DKK 6.3B impairment, highlighting competitive pressure from Eli Lilly.